menu
    • menu
    [{"orgOrder":0,"company":"ABL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ABL103","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"ABL103","moa":"||B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Merck & Co"},{"orgOrder":0,"company":"ABL Bio","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"TJ-CD4B","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Givastomig","moa":"||CLDN18.2","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"National OncoVenture","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Nov1501","moa":"Delta-like protein 4 (DLL4)","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ National OncoVenture","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ National OncoVenture"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Coave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Collaboration","leadProduct":"CTx-GBA1","moa":"GBA1","graph1":"Neurology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ABL301","moa":"IGF-1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ABL Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2022","type":"Collaboration","leadProduct":"ABL301","moa":"IGF-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"ABL Bio","amount2":1.0600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.0600000000000001,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ Sanofi"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ABL503","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"I-Mab Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TJ-L14B","moa":"PD-L1\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ABL501","moa":"PD-L1\/LAG3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ Undisclosed"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Themis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Themis Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ Themis Bioscience"},{"orgOrder":0,"company":"ABL Bio","sponsor":"HiFiBiO Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Partnership","leadProduct":"HFB30132A","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ HiFiBiO Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"ABL Bio \/ HiFiBiO Therapeutics"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Biocytogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"ABL Bio","amount2":2.73,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":2.73,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ GSK","highestDevelopmentStatusID":"1","companyTruncated":"ABL Bio \/ GSK"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Synaffix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ ABL Bio","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ ABL Bio"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ABL103","moa":"B7-H4\/4-1BB","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ABL Bio \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"ABL Bio \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by ABL Bio

    Menu

    ABL Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABL103

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

                            Details : ABL103 is a Large Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 08, 2025

                            Lead Product(s) : ABL103

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : GSK

                            Deal Size : $2,725.3 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ABL Bio Licenses Brain Drug Platform to GSK for Neuro Diseases

                            Details : Under the licensing agreement, GSK will develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $49.6 million

                            April 06, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : GSK

                            Deal Size : $2,725.3 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Givastomig,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : I-Mab Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

                            Details : TJ033721 (givastomig) is a potential best-in-class, Claudin 18.2 (CLDN18.2) x 4-1BB bispecific antibody, targeting CLDN18.2-positive tumor cells.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : Givastomig,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : I-Mab Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABL103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ABL Bio Collaborates to Evaluate ABL103 with KEYTRUDA® For Solid Tumors

                            Details : The collaboration aims to evaluate ABL103 in combination with MSD's anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with advanced or metastatic solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : ABL103,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biocytogen Collaborates With ABL Bio To Develop Bispecific Antibody-Drug Conjugates

                            Details : The collaboration aims to develop new bispecific antibody-drug conjugates using Biocytogen’s RenLite® mice platform that can produce fully human antibodies with diverse epitopes and high affinity.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Biocytogen

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABL103

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors

                            Details : ABL103 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 13, 2023

                            Lead Product(s) : ABL103

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TJ-L14B

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : I-Mab Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

                            Details : TJ-L14B/ABL503, is a differentiated PD-L1 x 4-1BB bispecific antibody, which is investigated in patients with progressive, locally advanced or metastatic solid tumors who are relapsed or refractory following prior lines of treatment.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2023

                            Lead Product(s) : TJ-L14B

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : I-Mab Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Recipient : Synaffix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products

                            Details : Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 13, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Recipient : Synaffix

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABL301

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Par...

                            Details : ABL301 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 07, 2023

                            Lead Product(s) : ABL301

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTx-GBA1

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : Coave Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Coave Therapeutics and ABL Enter Into Strategic Collaboration to Develop Gene Therapy Manufacturing Processes ...

                            Details : Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products including CTx-GBA1.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 09, 2022

                            Lead Product(s) : CTx-GBA1

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : Coave Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth